Testing to assess preexisting antibodies to the delivery vector (i.e., AAV) is one of the important factors in determining eligibility for gene therapies. Join us to learn more about antibody testing including AAV serotypes, antibody-mediated immunologic responses, testing methodologies (Total binding vs Neutralizing), titers, seroprevalence rates and a Sarepta-sponsored testing program to detect pre-existing total binding antibodies to the AAVrh74 vector.